DK3303616T3 - Fremgangsmåder til prognose af prostatakræft - Google Patents
Fremgangsmåder til prognose af prostatakræft Download PDFInfo
- Publication number
- DK3303616T3 DK3303616T3 DK16727361.4T DK16727361T DK3303616T3 DK 3303616 T3 DK3303616 T3 DK 3303616T3 DK 16727361 T DK16727361 T DK 16727361T DK 3303616 T3 DK3303616 T3 DK 3303616T3
- Authority
- DK
- Denmark
- Prior art keywords
- prostate
- procedures
- cancer
- prostate cancer
- prostate prostate
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15169788 | 2015-05-29 | ||
| PCT/EP2016/061886 WO2016193110A1 (en) | 2015-05-29 | 2016-05-26 | Methods of prostate cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3303616T3 true DK3303616T3 (da) | 2021-03-01 |
Family
ID=53298161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16727361.4T DK3303616T3 (da) | 2015-05-29 | 2016-05-26 | Fremgangsmåder til prognose af prostatakræft |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11827938B2 (da) |
| EP (1) | EP3303616B1 (da) |
| JP (1) | JP6745820B2 (da) |
| KR (1) | KR20180082328A (da) |
| CN (1) | CN108738329A (da) |
| BR (1) | BR112017025255B1 (da) |
| DK (1) | DK3303616T3 (da) |
| ES (1) | ES2861316T3 (da) |
| RU (1) | RU2760577C2 (da) |
| WO (1) | WO2016193110A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3502280A1 (en) * | 2017-12-21 | 2019-06-26 | Koninklijke Philips N.V. | Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables |
| EP3546598A1 (en) * | 2018-03-29 | 2019-10-02 | Koninklijke Philips N.V. | Post-surgical risk stratification based on pde4d variant expression, selected according to tmprss2-erg fusion status, and post-surgical clinical variables |
| EP3880256A4 (en) * | 2018-11-14 | 2022-08-03 | The Board of Trustees of the Leland Stanford Junior University | TARGETING MAKAPP-PDE4D3 COMPLEXES IN NEURODEGENERATIVE DISEASES |
| KR20220007132A (ko) * | 2019-05-08 | 2022-01-18 | 옥스포드 바이오다이나믹스 피엘씨 | 전립선암 및 림프종의 염색체 형태 마커 |
| EP3885453A1 (en) * | 2020-03-23 | 2021-09-29 | Koninklijke Philips N.V. | Prediction of radiotherapy response for prostate cancer subject based on dna repair genes |
| TR202007444A1 (tr) * | 2020-05-13 | 2021-11-22 | Aselsan Elektronik Sanayi Ve Tic A S | Hem manyeti̇k parçacik görüntüleme hem de manyeti̇k rezonans görüntüleme gerçekleşti̇ri̇lmesi̇ne i̇mkan sunan bi̇r terti̇bat ve bu terti̇bati i̇çeren bi̇r ci̇haz |
| WO2022099309A1 (en) * | 2020-11-06 | 2022-05-12 | Verily Life Sciences Llc | Artificial intelligence prediction of prostate cancer outcomes |
| WO2023129947A2 (en) * | 2021-12-29 | 2023-07-06 | Salk Institute For Biological Studies | Methods of lowering blood glucose and treating type 2 diabetes by activation of pde4d3 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794141B2 (en) | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
| US20050164220A1 (en) | 2001-03-19 | 2005-07-28 | Decode Genetics Ehf. | Susceptibility gene for human stroke: method of treatment |
| WO2004028341A2 (en) * | 2001-03-19 | 2004-04-08 | Decode Genetics Ehf. | Susceptibility gene for human stroke; methods of treatment |
| US20030220273A1 (en) | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphodiesterase 4D expression |
| EP1471153A3 (en) * | 2003-03-21 | 2005-06-15 | F. Hoffmann-La Roche Ag | Transcriptional activity assay |
| CA2521303A1 (en) | 2003-04-10 | 2004-10-21 | F. Hoffmann-La Roche Ag | The use of pde4d in the screening for medicaments against atherosclerosis |
| DE602006018513D1 (de) * | 2005-10-25 | 2011-01-05 | Roche Diagnostics Gmbh | Assoziation von pde4d-allelvarianten mit schlaganfall |
| GB0625321D0 (en) * | 2006-12-19 | 2007-01-24 | Univ Surrey | Cancer biomarker |
| WO2010059838A2 (en) * | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| BRPI1007620A2 (pt) | 2009-05-12 | 2016-02-23 | Koninkl Philips Electronics Nv | fosfodoestera 9a,composição metodo,metodo de aquisição de dados e imunoesnsaio para diagnostico, detecção, monitoramento ou prognostico do cancer de proposta, ou para diagnostico,detecção monitoramento ou prognostico da progressao do cancer de prostata. |
| CN102439176B (zh) | 2009-05-12 | 2018-11-23 | 皇家飞利浦电子股份有限公司 | 用作恶性的、激素-敏感的前列腺癌的标志物的磷酸二酯酶4d7 |
| WO2010131195A1 (en) * | 2009-05-12 | 2010-11-18 | Koninklijke Philips Electronics N.V. | Phosphodiesterase 4d7 as prostate cancer marker |
| EP2611941A4 (en) * | 2010-08-30 | 2014-01-22 | Myriad Genetics Inc | GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS |
| JP6351112B2 (ja) * | 2012-01-31 | 2018-07-04 | ジェノミック ヘルス， インコーポレイテッド | 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験 |
| CN102603676B (zh) * | 2012-02-20 | 2014-02-12 | 徐江平 | 一种能避免呕吐反应的磷酸二酯酶4抑制剂 |
-
2016
- 2016-05-26 US US15/577,969 patent/US11827938B2/en active Active
- 2016-05-26 JP JP2017561958A patent/JP6745820B2/ja active Active
- 2016-05-26 WO PCT/EP2016/061886 patent/WO2016193110A1/en active Application Filing
- 2016-05-26 EP EP16727361.4A patent/EP3303616B1/en active Active
- 2016-05-26 ES ES16727361T patent/ES2861316T3/es active Active
- 2016-05-26 BR BR112017025255-4A patent/BR112017025255B1/pt active IP Right Grant
- 2016-05-26 CN CN201680031469.9A patent/CN108738329A/zh active Pending
- 2016-05-26 RU RU2017146409A patent/RU2760577C2/ru active
- 2016-05-26 DK DK16727361.4T patent/DK3303616T3/da active
- 2016-05-26 KR KR1020177037352A patent/KR20180082328A/ko not_active Application Discontinuation
- 2016-12-01 US US15/366,362 patent/US11198909B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2760577C2 (ru) | 2021-11-29 |
| ES2861316T3 (es) | 2021-10-06 |
| US11198909B2 (en) | 2021-12-14 |
| WO2016193110A1 (en) | 2016-12-08 |
| JP2018521637A (ja) | 2018-08-09 |
| EP3303616A1 (en) | 2018-04-11 |
| US20170073778A1 (en) | 2017-03-16 |
| BR112017025255B1 (pt) | 2024-02-27 |
| US20180148795A1 (en) | 2018-05-31 |
| CN108738329A (zh) | 2018-11-02 |
| US11827938B2 (en) | 2023-11-28 |
| RU2017146409A3 (da) | 2020-03-27 |
| BR112017025255A2 (pt) | 2018-08-07 |
| EP3303616B1 (en) | 2021-01-06 |
| RU2017146409A (ru) | 2019-07-02 |
| KR20180082328A (ko) | 2018-07-18 |
| JP6745820B2 (ja) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
| DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| MA43259A (fr) | Liants ctla4 | |
| MA43258A (fr) | Liants pd1/ctla4 | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3233882T3 (da) | Fluorinerede cykliske dinukleotider til cytokininduktion | |
| DK3468965T3 (da) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3303618T3 (da) | Fremgangsmåder til prognose af prostatacancer | |
| DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
| DK3303616T3 (da) | Fremgangsmåder til prognose af prostatakræft | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3302063T3 (da) | Fremgangsmåde til stimulering af frø | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3117216T3 (da) | Fremgangsmåde til detektering af en solid tumor-cancer | |
| DE102016117105A8 (de) | Antenneneinrichtung | |
| DK3052102T3 (da) | Sammensætninger til behandling af cancere |